PolyGenX

PolyGenX appears to be the corporate holding structure associated with Polyplus, a France-based life science tools and upstream solutions business focused on nucleic acid delivery, transfection reagents, plasmid design, and plasmid/protein manufacturing for cell and gene therapy and biologics production. In practice, the operating business is marketed as Polyplus or Polyplus-transfection, now part of Sartorius following a completed acquisition in July 2023. The company provides commercial products and services used in viral vector production, non-viral delivery workflows, recombinant protein production, and related research applications rather than developing its own therapeutic drug pipeline. Its core value proposition is enabling efficient upstream process development and manufacturing from research through GMP-oriented workflows. The requested name "PolyGenX" most plausibly maps to the legal entities "PolyGenX A" and "PolyGenX 2," which appear to sit within the Polyplus/Sartorius corporate structure.